CellCarta

Will you be at #WRIB? Register for Workshop Th2 to hear from Laïla-Aïcha Hanafi in specialized workshop 2! Can't make it? Our team will be at Booth #13. Book a meeting today to make sure you don't miss the chance to talk: buff.ly/gc5U7l8 #SpectralFlow #FlowCytometry

PRESS RELEASE: CellCarta's announces an expanded multi-year strategic partnership with Biofidelity, including exclusivity for Aspyre® Lung in clinical trial settings. Read the full release: cellcarta.com/science-hub/bi…

It is with profound sadness that we share the news that our dear colleague, Mark Kockx, passed away last week. We extend our condolences to Mark’s family, friends and colleagues as we remember his contributions to science and his commitment to advancing cancer research.

We're thrilled to be attending World CB & CDx in London! Visit us at Booth#4 👋 From preclinical work through to CDx development, CellCarta's integrated capabilities can accelerate your biomarker and CDx development. Book a meeting with our team today: buff.ly/u5V8kPo

Navigating the FDA’s guidance is key to advancing antibody-drug conjugate (ADC) development. Our blog breaks down what you need to know, with expert insights on regulatory expectations and best practices for success. Read it today: buff.ly/RnUGkFT

CellCarta is attending BIO China 2026, from March 12–14 in Suzhou. Our wholly-owned lab in China offers immune monitoring, genomics, proteomics and histopathology services with globally standardized SOPs. Learn how we can support your global projects: buff.ly/llRwUs1

We're proud to be an Olink Certified Service Provider- which means our facilities meet the same stringent requirements as Olink's own. We offer everything from targeted 48-plex panels to the Reveal, which analyses over 1000 proteins. Learn more: buff.ly/uGRdEs7

We're at Japan Bioanalysis Forum! Drop by our booth at #JBF2026 to learn more about our 3 posters with Pierre Gontard and Luca Genovesi, and see how we support studies across the APAC region and around the world. Read the full posters: buff.ly/Cnb9iFc

Official Release: CellCarta Appoints Ehab A. El-Gabry, MD, as Chief Medical Officer & Head of Companion Diagnostics to Advance CDx Strategy, Digital Pathology and AI Read the full release for more: buff.ly/cC7BBiG

CellCarta has performed more than 80,000 PD-L1 tests and supported > 100 registrational trials with our PD-L1 assays. Interested in applying one of our PD-L1 assays to your program? Reach our to our experts to see which option is right for you. buff.ly/3LYV3zl

We'll be at the ImmunoMark Summit in London! Will we see you there? Busy schedule? Drop by Booth #10 or book a meeting with the team to learn how we can support your biomarker strategy across your immuno-oncology projects. buff.ly/i2zCWDx #ImmunoMark2026 #Biomarkers

Our experts identified key trends in the cell therapy landscape. Discover what that means for clinical testing programs. Find out how in our trends report: buff.ly/L7MMLZo

Happy Lunar New Year! As we enter this new year, we remain committed to delivering excellence in every study and supporting development of new therapeutics with expert insights. Wishing you and your families health, prosperity, and happiness! 🏮✨

Have you heard about CellEngine? Our cytometry software makes your analysis simpler and easier with: 🌟Blazing fast algorithms 🌟Metadata-driven interfaces 🌟Advanced charting and visualizations 🌟Automatic supervised gating Test drive it today 👉 buff.ly/fhSZIDg

🗺️Navigating global regulatory requirements can be complex, but with CellCarta’s worldwide footprint and local expertise, your projects are in good hands. We supports regulatory needs including in China, the EU and the US. Contact our team today 👉 buff.ly/KNerdyA

On February 11th, we're thrilled to celebrate the amazing women in science who work across our sites to support your global clinical trials. Today, we're highlighting a few members of the CellCarta team! Happy International Day of Women and Girls in Science! 👩‍🔬🔬🧬❤️

Interested in M-protein monitoring in multiple myeloma using microsampling and intact mass analysis? Don't miss this poster! Read the full poster or reach out to learn more about how CellCarta’s mass spectrometry expertise can support your studies 🔗 buff.ly/6nq1Cod

🌠Spatial biology methods generate exceptionally rich datasets that capture multiple layers of tissue complexity. Learn more about our standardized workflow for mIF analysis in our recent article: buff.ly/f23DaSV

Discover our global biorepository services in Belgium, the USA and China! 🌟 We offer storage temperatures ranging from room temperature, -80C to liquid nitrogen 🌟 StarLIMS systems actively track all samples Reach out for more information 👉 buff.ly/BHFowiZ

February 4th is World Cancer Day, a time to bring awareness to the importance of advancing diagnostics and treatments. We are proud to help improve patient outcomes by contributing to the development of new diagnostics and therapeutics. #UnitedByUnique #WorldCancerDay